Xcout Intel
Oleander Medical Technologies LLC
Oleander Medical Technologies is developing a cancer treatment called Targeted Osmotic Lysis (TOL), which destroys malignant cells by forcing them to absorb excessive sodium and burst. The therapy combines an existing heart medication with an investigational pulsed electric field device to target cancers with elevated sodium channel expression while leaving healthy cells unharmed.
Subscribe to see Oleander Medical Technologies LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Oleander Medical Technologies LLC at a glance
Oleander Medical Technologies LLC is a biotechnology company headquartered in United States. It has raised at least $1.1M across the 2 funding rounds on record. Its most recent funding round raised $500,000 in June 2024. Xcout tracks 4 named people at Oleander Medical Technologies LLC, including Paige R. Miller, J.D. (President & CEO).
Oleander Medical Technologies LLC leadership
- Paige R. Miller, J.D.President & CEO
- Hank MillsChief Financial Officer
- Dennis Paul, Ph.D.Chief Science Officer
- Harry J. Gould, III, M.D., Ph.D.Chief Medical Officer
Oleander Medical Technologies LLC funding rounds
At least $1.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $500,000 | — | |
| SEC Form D filing | $650,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Oleander Medical Technologies LLC competitors
A few of Oleander Medical Technologies LLC's closest competitors — see the full list of competitors and alternatives →
Haniva Technology LLC is a biotechnology company that develops patented combination therapies and drug delivery devices to treat various forms of cancer. Its research focuses on using non-thermal plasma alongside hypoxia-activated DNA-damaging agents to selectively target and reduce tumor volume, prevent metastasis, and serve as an adjuvant treatment following tumor resection.
KAIO Therapy, LLC develops an Immune Activating Heat Therapy (IAHT) technology designed to treat cancer patients by combining hyperthermia with immunotherapy. The system utilizes injected nanoparticles and an alternating magnetic field device to induce controlled heat within tumors, which destroys cancer cells and activates the patient's immune system against primary and metastatic tumors.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development of therapies using Tumor Treating Fields.
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. This technology finds particular application in treating gliomas, a form of brain tumor. The company was established in 2016 and is headquartered in Road Town, British Virgin Islands.
Kortuc Inc. develops cancer radiotherapy solutions, specifically offering an innovative radiosensitizer designed to eliminate tumor hypoxia and maximize the effectiveness of radiation treatment. The company serves the medical and oncology research sectors by advancing clinical trials and expanding treatment options for cancer patients.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Get Oleander Medical Technologies LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Oleander Medical Technologies LLC in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access